Literature DB >> 19549768

HPV16 tumor associated macrophages suppress antitumor T cell responses.

Ana Paula Lepique1, Katia Regina Perez Daghastanli, Iolanda Midea Cuccovia, Luisa Lina Villa.   

Abstract

PURPOSE: High-risk human papillomavirus (HPV) is the main etiologic factor for cervical cancer. The severity of HPV-associated cervical lesions has been correlated to the number of infiltrating macrophages. The objective of this work is to characterize the role of tumor-associated macrophages (TAM) on the immune cellular response against the tumor. EXPERIMENTAL
DESIGN: We used the HPV16 E6- and E7-expressing TC-1 mouse tumor model to study the effect of TAM on T-cell function in vitro, and depleted TAM, using clodronate-containing liposomes, to characterize its role in vivo.
RESULTS: TAM, characterized by the positive expression of CD45, F4/80, and CD11b, formed the major population of infiltrating tumor cells. TAM displayed high basal Arginase I activity, producing interleukin-10 (IL-10); they were resistant to iNOSII activity induction, therefore reversion to M1 phenotype, when stimulated in vitro with lipopolysaccharide/IFNgamma, indicating an M2 phentoype. In cultures of isolated TAM, TAM induced regulatory phenotype, characterized by IL-10 and Foxp3 expression, and inhibited proliferation of CD8 lymphocytes. In vivo, depletion of TAM inhibited tumor growth and stimulated the infiltration of tumors by HPV16 E7(49-57)-specific CD8 lymphocytes, whereas depletion of Gr1(+) tumor-associated cells had no effect.
CONCLUSIONS: M2-like macrophages infiltrate HPV16-associated tumors causing suppression of antitumor T-cell response, thus facilitating tumor growth. Depletion or phenotype alteration of this population should be considered in immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549768     DOI: 10.1158/1078-0432.CCR-09-0489

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  60 in total

1.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

Review 2.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 3.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

4.  Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.

Authors:  Nafiseh Pakravan; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2011-02-26       Impact factor: 3.667

5.  Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer.

Authors:  Marlies Schrevel; E Michelle Osse; Frans A Prins; J Baptist M Z Trimbos; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Int J Oncol       Date:  2017-05-03       Impact factor: 5.650

6.  Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.

Authors:  Pavel Gabriel; Katarina Babiarova; Kamila Zurkova; Jitka Krystofova; Petr Hainz; Luda Kutinova; Sarka Nemeckova
Journal:  Viral Immunol       Date:  2012-10       Impact factor: 2.257

Review 7.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

8.  Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Authors:  Henok Eyob; Huseyin Atakan Ekiz; Yoko S Derose; Susan E Waltz; Matthew A Williams; Alana L Welm
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

9.  Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth.

Authors:  Aline Bolpetti; João S Silva; Luisa L Villa; Ana Paula Lepique
Journal:  BMC Immunol       Date:  2010-06-07       Impact factor: 3.615

10.  Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.

Authors:  Chi-Mu Chuang; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  J Biomed Sci       Date:  2010-04-28       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.